open access

Vol 60, No 1 (2009)
Original papers
Published online: 2008-12-19
Submitted: 2013-02-15
Get Citation

The role of bone metabolic markers in qualification for treatment of osteoporosis. Results of POMOST study

Jerzy Przedlacki, Zbigniew Bartoszewicz, Krystyna Księżopolska-Orłowska, Agnieszka Kondracka, Artur Grodzki, Tomasz Bartuszek, Dorota Bartuszek, Andrzej Świrski, Ewa Loth, Jan Musiał, Elżbieta Łuczak, Paweł Teter, Andrzej Łasiewicki, Andrzej Walkiewicz, Iwona Drozdowska-Rusinowicz
Endokrynologia Polska 2009;60(1):25-32.

open access

Vol 60, No 1 (2009)
Original papers
Published online: 2008-12-19
Submitted: 2013-02-15

Abstract


Introduction: Increased bone turnover markers (BTM) level is consider as independent risk factor of bone fracture. However, it was not used in 10-year probability of bone fracture method (FRAX) proposed by WHO, which helps in qualification of patients for pharmacological treatment of osteoporosis. The aim of the study was to evaluate the usefulness of BTM in qualification for pharmacological treatment of osteoporosis.
Material and methods: The study was performed in 152 subjects (20 men and 132 women) referred to Krajowe Centrum Osteoporozy. One-hundred thirty two of them were qualified for pharmacological treatment and 20 for prophylaxis on the basis of qualitative method. The following BTM were examined in all patients: of bone formation - N-terminal propeptide of procolagen type I (PINP) and N-mid osteocalcin (OC) and of bone resorption - C-terminal cross-linked telopeptide of collagen type I (CTx).
Results: The values over that considered as independent fracture risk (in women only, no data for men) were found in 39 women with PINP, 39 with OC and 41 with CTx. Part of women had decreased serum BTM (10 women 3 BTM and 35 with 1 at least). There were not significant differences in serum BTM depending on the presence of clinical fracture risk factors: osteoporotic fracture in past, osteoporotic hip fracture in parents, chronic treatment with glucocorticosteroids and qualification for pharmacological treatment on the basis of qualitative and FRAX method. There was no significant difference in the presence of fracture risk factors depending on increased or decreased serum BTM.
Conclusions: Results of the study did not show the practical use of BTM in qualification for pharmacological treatment of osteoporosis.

Abstract


Introduction: Increased bone turnover markers (BTM) level is consider as independent risk factor of bone fracture. However, it was not used in 10-year probability of bone fracture method (FRAX) proposed by WHO, which helps in qualification of patients for pharmacological treatment of osteoporosis. The aim of the study was to evaluate the usefulness of BTM in qualification for pharmacological treatment of osteoporosis.
Material and methods: The study was performed in 152 subjects (20 men and 132 women) referred to Krajowe Centrum Osteoporozy. One-hundred thirty two of them were qualified for pharmacological treatment and 20 for prophylaxis on the basis of qualitative method. The following BTM were examined in all patients: of bone formation - N-terminal propeptide of procolagen type I (PINP) and N-mid osteocalcin (OC) and of bone resorption - C-terminal cross-linked telopeptide of collagen type I (CTx).
Results: The values over that considered as independent fracture risk (in women only, no data for men) were found in 39 women with PINP, 39 with OC and 41 with CTx. Part of women had decreased serum BTM (10 women 3 BTM and 35 with 1 at least). There were not significant differences in serum BTM depending on the presence of clinical fracture risk factors: osteoporotic fracture in past, osteoporotic hip fracture in parents, chronic treatment with glucocorticosteroids and qualification for pharmacological treatment on the basis of qualitative and FRAX method. There was no significant difference in the presence of fracture risk factors depending on increased or decreased serum BTM.
Conclusions: Results of the study did not show the practical use of BTM in qualification for pharmacological treatment of osteoporosis.
Get Citation

Keywords

risk factors; bone densitometry; treatment; bone turnover markers; osteoporosis; fracture

About this article
Title

The role of bone metabolic markers in qualification for treatment of osteoporosis. Results of POMOST study

Journal

Endokrynologia Polska

Issue

Vol 60, No 1 (2009)

Pages

25-32

Published online

2008-12-19

Bibliographic record

Endokrynologia Polska 2009;60(1):25-32.

Keywords

risk factors
bone densitometry
treatment
bone turnover markers
osteoporosis
fracture

Authors

Jerzy Przedlacki
Zbigniew Bartoszewicz
Krystyna Księżopolska-Orłowska
Agnieszka Kondracka
Artur Grodzki
Tomasz Bartuszek
Dorota Bartuszek
Andrzej Świrski
Ewa Loth
Jan Musiał
Elżbieta Łuczak
Paweł Teter
Andrzej Łasiewicki
Andrzej Walkiewicz
Iwona Drozdowska-Rusinowicz

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl